Albert Bourla, Chairman & CEO of Pfizer, reported no stock transactions as of 11/29/2024. The announcement indicates that there were no non-derivative securities transactions recorded for this period.This report is part of the regular disclosure requirements for executives, ensuring transparency in stock dealings. The absence of transactions suggests no recent changes in Bourla's stock holdings in Pfizer.Investors should note that while no transactions were reported, this does not necessarily imply future actions or intentions regarding stock holdings. The report serves as a compliance measure, reflecting the current status of stock transactions by the CEO.

Albert Bourla, Chairman & CEO of Pfizer, reported no stock transactions as of 11/29/2024. The announcement indicates that there were no non-derivative securities transactions recorded for this period.This report is part of the regular disclosure requirements for executives, ensuring transparency in stock dealings. The absence of transactions suggests no recent changes in Bourla's stock holdings in Pfizer.Investors should note that while no transactions were reported, this does not necessarily imply future actions or intentions regarding stock holdings. The report serves as a compliance measure, reflecting the current status of stock transactions by the CEO.